Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-15T10:16:16.987Z Has data issue: false hasContentIssue false

Clozapine-Induced Agranulocytosis Treated with Granulocyte Macrophage Colony Stimulating Factor

Published online by Cambridge University Press:  02 January 2018

Ran Oren*
Affiliation:
Department of Medicine, Hadassah University Hospital, Mount Scopus, PO Box 24035, Jerusalem 91240, Israel
Elaine Granat
Affiliation:
Department of Medicine, Hadassah University Hospital, Jerusalem
Shlomo Shtrussberg
Affiliation:
Department of Psychiatry, Sarah Herzog Memorial Hospital, Jerusalem
Yaacov Matzner
Affiliation:
Haematology Unit, Hadassah University Hospital, Jerusalem
*
Correspondence

Abstract

Clozapine-induced agranulocytosis is usually reversible after discontinuation of the drug. A patient who developed agranulocytosis after termination of clozapine therapy responded to treatment with granulocyte macrophage colony stimulating factor.

Type
Brief Reports
Copyright
Copyright © Royal College of Psychiatrists, 1993 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bonilla, M. A., Gillio, A. P., Ruggeiro, M., et al (1989) Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. New England Journal of Medicine, 320, 15741582.CrossRefGoogle ScholarPubMed
Green, A. I. & Salzman, C. (1990) Clozapine: benefits and risks. Hospital and Community Psychiatry, 41, 379380.Google Scholar
Hammond, W. P., Price, T. H., Souza, L. M., et al (1989) Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. New England Journal of Medicine, 320, 13061310.CrossRefGoogle ScholarPubMed
Kane, J., Honigfeld, F., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789796.Google Scholar
Kojima, S., Tsuchida, M. & Matsuyama, T. (1992) Myelodysplasia and leukemia after treatment of aplastic anaemia with G-CSF. New England Journal of Medicine, 326, 1294.Google Scholar
Liedemann, A., Herrmann, F., Oster, W., et al (1989) Haematologic effects of GM-CSF in patients with malignancy. Blood, 74, 26442651.CrossRefGoogle Scholar
Lopez, A. F., Williamson, J., Gamble, J. R., et al (1986) Recombinant human granulocyte-macrophage colony stimulating factor stimulates in vitro mature human neutrophil and eosinophil function surface receptor expression and survival. Journal of Clinical Investigation, 78, 12201228.Google Scholar
Metcalf, D., Begley, C. G., Johnson, G. R., et al (1986) Biological properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood, 67, 3745.CrossRefGoogle ScholarPubMed
Salzman, C. (1990) Mandatory monitoring for side effects - the ‘bundling’ of clozapine. New England Journal of Medicine, 323, 827829.Google Scholar
Sieff, C. A., Emerson, S. G., Donahue, R. E., et al (1985) Human recombinant granulocyte-macrophage colony stimulating factor: a multi-lineage hematopoiation. Science, 230, 11711173.Google Scholar
Steward, W. P., Scarffe, J. H., Diriv, L. Y., et al (1990) Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. British Journal of Cancer, 61, 749754.Google Scholar
Vadhan-Raj, S., Buescher, S., Broxmeyer, H. E., et al (1988) Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. New England Journal of Medicine, 319, 16281634.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.